Tracon Pharmaceuticals (United States)

Recent papers from Tracon Pharmaceuticals (United States)

1. The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloadsiScience · 2026
2. Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancernpj Precision Oncology · 2026
3. CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary TumorsClinical Cancer Research · 2026
4. Resilience and vulnerabilities of tumor cells under purine shortage stress.2025
5. Recent developments in sustained-release and targeted drug delivery applications of solid lipid nanoparticlesJournal of Microencapsulation · 2025
6. Resilience and vulnerabilities of tumor cells under purine shortage stress2025
7. Anti-Endoglin monoclonal antibody prevents the progression of liver sinusoidal endothelial inflammation and fibrosis in MASHLife Sciences · 2025
8. The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRAS G12C Inhibitors in Preclinical ModelsCancer Research Communications · 2025
9. Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-scorenpj Precision Oncology · 2024
10. A genome-wide CRISPR screen reveals that antagonism of glutamine metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell deathCancer Letters · 2024
11. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancerScience Advances · 2024
12. Targeting glutamine dependence with DRP‐104 inhibits proliferation and tumor growth of castration‐resistant prostate cancerThe Prostate · 2023
13. Targeting pancreatic cancer metabolic dependencies through glutamine antagonismNature Cancer · 2023
14. Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trialCommunications Medicine · 2023
15. KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLCJournal of Thoracic Oncology · 2023
16. Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and MetastasisClinical Cancer Research · 2023
17. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer2023
18. A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancerBreast Cancer Research and Treatment · 2023
19. Neuroblastoma Tumor-Associated Mesenchymal Stromal Cells Regulate the Cytolytic Functions of NK CellsCancers · 2022
20. A Phase I/II Study of Preoperative Letrozole, Everolimus, and Carotuximab in Stage 2 and 3 Hormone Receptor-positive and Her2-negative Breast Cancer.2022